The Regulation of the Pharmaceutical Industry

The Oxford Handbook of Regulation

Volumn , Issue , 2010, Pages

  Towse, Adrian ^a   Danzon, Patricia M ^b  

^a Office of Health Economics (OHE)   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Government granted patents; Market power; Pharmaceutical industry; Private sector investment; Public policy

Indexed keywords

EID: 84924873733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780199560219.003.0022     Document Type: Chapter

References (59)

1. Acemoglu, D. & Linn, J. (2004). 'Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry', The Quarterly Journal of Economics, 119(3): 1049-1090.
2. Averch, H. & Johnson, L. L. (1962), 'Behaviour of the Firm under Regulatory Constraints', American Economic Review, 52: 1052-1069.
3. Berndt, E. R. (2005). The 'United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned?' Taipei, Taiwan: International Conference on Pharmaceutical Innovation.
4. Boston Consulting Group (1993). The Contribution of Pharmaceutical Companies: What's at Stake for America, Boston, MA: Boston Consulting Group.
5. Chaudhuri S. & Goldberg, P. K. (2006). 'Estimating the Effect of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India', American Economic Review, 95(5): 1477-1514.
6. Clarkson, K. W. (1996). 'The Effects of Research and Promotion on Rates of Return', in R.B. Helms (ed.), Competitive Strategies in the Pharmaceutical Industry, Washington, DC: American Enterprise Institute Press.
7. Coleman, M. S., Sangrujee, N., Zhou, F., & Chu, S. (2005). 'Factors Affecting US Manufacturers' Decisions to Produce Vaccines.' Health Affairs, 24(3): 635-42.
8. Danzon, P. M. (2007). 'Note on the Office of Fair Trade Report.' Unpublished paper.
9. Danzon, P. M. & Chao, L. W. (2000). 'Does Regulation Drive Out Competition in Pharmaceutical Markets?' Journal of Law & Economics, 43(2): 311-57.
10. Danzon, P. M. & Epstein, A. J. (2008). 'Effects of Regulation on Drug Launch and Pricing in Interdependent Markets', NBER Working Papers 14041, National Bureau of Economic Research.
11. Danzon, P. M. & Furukawa, M. F. (2003). 'Prices and Availability of Pharmaceuticals: Evidence from Nine Countries'. Health Affairs, 22(6): W521-W536.
12. Danzon, P. M. & Furukawa, M. F. (2006). 'Prices and Availability of Biopharmaceuticals: An International Comparison.' Health Affairs, 25(5): 1353-1362.
13. Danzon, P. M. & Towse, A. (2003). 'Differential Pricing for Pharmaceuticals: Reconciling Access, R&D, and Patents', International Journal of Health Care Finance and Economics, 3: 183-205.
14. Danzon, P. M. & Towse, A. (2005). 'Theory and Implementation of Differential Pricing for Pharmaceuticals', in K. Maskus and J. Reichman (ed.), International Public Goods and Transfer of Technology under a Globalized Intellectual Property Regime, Cambridge: Cambridge University Press.
15. Danzon, P. M. Nicholson, S., & Epstein, A.J. (2007). 'Mergers and Acquisitions in the Pharmaceutical and Biotech Industries', Managerial and Decision Economics, 28(4-5): 307-28.
16. Danzon, P. M. Nicholson, S., & Pereira, N. S. (2005). 'Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances', Journal of Health Economics, 24(2): 317-39.
17. Danzon, P. M. Pereira, N. S., & Tejwani, S. (2005). 'Vaccine Supply: A Cross-National Perspective', Health Affairs, May/June.
18. Danzon, P. M. Wang, Y. R., & Wang, L. (2005). 'The Impact of Price Regulation on the Launch Delay of New Drugs-evidence From Twenty-Five Major Markets in the 1990s', Health Economics, 14(3): 269-92.
19. DiMasi, J. A. & Paquette, C. (2004). 'The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and the Timing of Development', Pharmacoeconomics, 22: 1-14.
20. DiMasi, J. A. Hansen, R. W., Grabowski, H. G. (2003). 'The Price of Innovation: New Estimates of Drug Development Costs', Journal of Health Economics, 22(2): 151-85.
21. emea/chmp (2005). 'Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues', http://www.emea.eu.int/prfs/human/biosimilar4283295en.pdf.
22. emea (2006). 'Biotech Medicines: First Biosimilar Drug on EU market', European Commission. Press release, http://www.europa.eu.int/rapid/pressReleasesAction.do?reference =IP/06/511&format=HTML&aged=0&language=EN&guiLanguage=en.
23. European Commission Competition DG (2008). 'Pharmaceutical Sector Inquiry Preliminary Report', DG Competition Staff Working Paper. 28th January 2008.
24. Federal Trade Commission (FTC) (2002). Generic Drug Entry Prior to Patent Expiration, London: FTC.
25. Food and Drug Administration (FDA) (1997). Food and Drug Administration Modernization Act of 1997.
26. Food and Drug Administration (FDA) (2005). Fast Track, Priority Review and Accelerated Approval: Oncology Tools, Center for Drug Evaluation and Research & Food and Drug Administration.
27. Fink, C. (2001). 'Patent Protection, Transnational Corporations, and Market Structure: A Simulation Study of the Indian Pharmaceutical Industry', Journal of Industry, Competition and Trade, 1(1): 101-21.
28. Frank, R. G, Berndt, E. R., Donohue, J., Epstein, A., & Rosenthal, M. (2002). Trends in Direct-to-Consumer Advertising of Prescription Drugs, Menlo Park, CA: The Kaiser Family Foundation.
29. Garrison, L. & Towse, A. (2003), 'The Drug Budget Silo Mentality in Europe: An Overview', Value in Health, 6(1): 1-9.
30. Grabowski, H. G. (2002). Patents and New Product Development in the Pharmaceutical and Biotechnology Industries, Duke University.
31. Grabowski, H. G. & Vernon, J. M. (1990). 'A New Look at the Returns and Risks to Pharmaceutical R&D'. Management Science, 36(7): 804-21.
32. Grabowski, H. G. & Vernon, J. M. (1992). 'Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act', Journal of Law and Economics, 35(2): 331-50.
33. Grabowski, H. G. & Vernon, J. M. (1996). 'Prospects for Returns to Pharmaceutical R&D Under Health Care Reform', in R. B. Helms (ed.), Competitive Strategies in the Pharmaceutical Industry, Washington, DC: The American Enterprise Institute Press.
34. Grabowski, H. G. & Vernon, J. M. (2000). 'Effective Patent Life in Pharmaceuticals', International Journal of Technology Management, 19(1-2): 98-120.
35. Grabowski, H. G. & Vernon, J. M. (2002). 'Returns on Research and Development for 1990s New Drug Introductions', Pharmacoeconomics, 20: 11-29.
36. Health Partnership Database (2008). www.health-partnerships-database.org.
37. Henderson, R. & Cockburn, I. (1996). 'Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery', Rand Journal Of Economics, 27(1): 32-59.
38. Joskow, P. (1974). 'Inflation and Environmental Concern: Structural Change in the Process of Public Utility Regulation', Journal of Law and Economics, 17(2): 291-327.
39. Kremer, M. (2002). 'Pharmaceuticals and the Developing World', Journal of Economic Perspectives, 16(4).
40. Kuhlik, B. N. (2004). 'The Assault on Pharmaceutical Intellectual Property', University Of Chicago Law Review, 71(1): 93-109.
41. Kyle, M. (2007). 'Pharmaceutical Price Controls and Entry Strategies', Review of Economics and Statistics, 89(1): 88-99.
42. Lanjouw, J. O. (2005). 'Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry', NBER Working Papers 11321, National Bureau of Economic Research.
43. Lichtenberg, F. R., & Philipson, T. J. (2002). 'The Dual Effects of Intellectual Property Regulations: Within-and Between-Patent Competition in the US Pharmaceuticals Industry', Journal of Law & Economics, 45(2): 643-72.
44. Lichtenberg, F. R. & Waldfogel, J. (2003). 'Does Misery Love Company? Evidence from Pharmaceutical Markets Before and After the Orphan Drug Markets', NBER Working Paper 9750.
45. Longman, R. (2004). 'Why Early-Stage Dealmaking is Hot', in Vivo: The Business and Medicine Report, p. 28.
46. Longman, R. (2006). 'The Large Molecule Future', in Vivo: The Business and Medicine Report, p. 3.
47. Lopez-Casasnovas, G. & Puig-Junoy, J. (2000). 'Review of the Literature on Reference Pricing', Health Policy, 54(2): 87-123.
48. Mahmoud, A., Danzon, P., Barton, J., & Mugerwa, R. (2006). 'Product Development Priorities', in D. Jamison and J. Bremen (eds.), Disease Control Priorities in Developing Countries, Institute of Medicine, April 2006.
49. Munnich, F. E. & Sullivan, K. (1994). 'The Impact of Recent Legislative Change in Germany', PharmacoEconomics, 94(6): S22-S27.
50. Office of Fair Trading (OFT) (2007). 'The Pharmaceutical Price Regulation Scheme'. http://www.oft.gov.uk/advice:and_resources/resource:base/market-studies/completed/price-regulation.
51. Pammolli, F. Riccaboni, M. (2001). 'Innovation and Markets for Technology in the Pharmaceutical Industry', in H. E. Kettler (ed.), Consolidation and Competition in the Pharmaceutical Industry, Office of Health Economics, London.
52. Pammolli, F. Riccaboni, M. (2004). 'Market Structure and Drug Innovation', Health Affairs, 23(1): 48-50.
53. Ridley, D., Grabowski, H. G., & Moe, J. L. (2006). 'Developing Drugs for Developing Countries', Health Affairs, 25(2): 313-24.
54. Schulenburg, J. M. G. & Schoffski, O. (1994). 'Transformation des Gesundheitswesens im Spannungsfeld zwischen Kostendampfung und Freiheit, Eine okonomische Analyse des veranderten Uberweisungs-und Einweisungsverhaltens nach den Arzneimittelregulierungen des GSG (Transformation of the Health Care System, An Economic Analysis of the Changes in Referrals and Hospital Admissions after the Drug Budget of the Health Care Reform Act of 1992)', in P. Oberender (ed.), Probleme der Transformation im Gesundheitswesen, Baden-Baden: Nomos.
55. Scott M. F. (1999). 'Entry Decisions in the Generic Pharmaceutical Industry', Rand Journal of Economics, 30(3): 421-40.
56. Scott M. F. (2000). 'Barriers to Entry, Brand Advertising, and Generic Entry in the US Pharmaceutical Industry', International Journal Of Industrial Organization, 18(7): 1085-1104.
57. Tufts Center for the Study of Drug Development (2003). 'FDA's Fast Track Initiative Cut Total Drug Development Time by Three Years, According to Tufts CSDD', 2005, from http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=34.
58. Walsh, J. P., Arora, A., & Cohen, W. M. (2003). 'Effects of Research Tools Patents and Licensing on Biomedical Research', in W. M. Cohen and S. Merrill (eds.), Patents in the Knowledge Based Economy, National Research Council of the National Academies: National Academies Press.
59. Watal, J. (2000). 'Pharmaceutical Patents, Prices and Welfare Losses: Policy Options for India Under the WTO TRIPS Agreement', World Economy, 23(5): 733-52.